Geriatric frailty

Assessment tools and importance of frailty for clinical practice

Eva Topinková

Department of Geriatrics
First Faculty of Medicine Charles University
And General Faculty Hospital in Prague


topinkova.eva@vfn.cz





Heterogeneity of older population


CONCEPTUAL FRAMEWORK



Adverse outcomes
Physical
Functional
Decline
or
Death

Michel 2007, adapted

Aging, multimorbidity and frailty




Thillainadesan J et al Frailty, a multisystem ageing syndrome, *Age Ageing*, 2020;49 (5):758–763

Prevalence of frailty English Longitudinal Study of Ageing (ELSA)

Gale C.R. Age and Ageing. 2015

Weighted prevalence of frailty in 2008-2009 according to age and sex



Frailty

Definition and clinical correlates

Defining frailty

Age-related alteration in physiology and pathology that leads to vulnerability with loss of organ system reserve, limited capacity to respond to internal and environmental stresses, unstable homeostasis and **poor medical and functional outcomes.**

Studenski JAGS 2004;62:1560-66,Ferrucci J Endocrinol Invest. 2002;25:10-5

A biologic syndrome of decreased reserve and resistance to stressors, resulting from cumulative declines across multiple physiologic systems and causing vulnerability to adverse outcomes.

Fried LP et al. J Gerontol A Biol Sci Med Sci 2001

What does it mean clinically to be frail?


- aged over 75 years with co-morbidities that may include dementia, reduced renal function
- reduced resilience to external stressors (may take longer to recover from illnesses such as urinary tract infections or from incidents such as falls)
- an apparently minor event can trigger a major change
- episodes of acute illness during which their health deteriorates before improving, but they do not recover to the same level of functional ability that they had before the event.

Frailty is associated with an array of adverse health outcomes

- Decreased quality of life
- · Loss of fitness, loss of autonomy, disability, dependency
- Multimorbidity
- Polypharmacy (drug-drug, drug-disease interaction, inappropriate prescribing, adverse drug events)
- Falls, depression, delirium
- Mortality
- + health Services use (physician's visits, emergency, (re)hospitalization, community Services, longterm care

Components of frailty

- Physical frailty (and sarcopenia)
- Cognitive frailty
- Social frailty
- Pharmacologic frailty?



The need of screening for frailty (distinguish between these "old cars")



Geriatric patient

(or subject at risk)

versus

Older patient (chronologically old)

Frailty phenotype

SYMPTOMS= Frailty criteria

Weight loss (unintentional) Weakness (grip strength) **Fatigue** Low physical activity Slow walking speed





SIGNS

he Journals of gerontology BIOLOGICAL SCIENCES AND MEDICAL SCIENCES

56:M146-M157 (2001)

Sarcopenia Osteopenia **Balance** and gait abnormalities, falls **Deconditioning** Undernutrition


Fried L., 2001

Criteria of frailty and their measurements

Characteristic	WHAS	CHS
Weight loss	► BMI < 18.5 or Weight at age 60 minus weight at exam > 10% of weight at age 60	Lost >10 pounds unintentionally in last year
Exhaustion	Any of:	Either of:
	Low usual energy level (≤3) Felt unusually tired in last month	Felt that everything I did was an effort in last week
	Felt unusually weak in last month	Could not get going in last week
Slowness	Walking 4 m (speed) in:	Walking 15 feet (time) in:
	≤0.65 m/s for height ≤159 cm	<7 seconds for height <159 cm
	< 0.76 m/s for height > 159 cm	<6 seconds for height > 159 cm
Low activity level	< 90 kcal of physical expenditure on activity	<270 kcal of physical expenditure on
	scale (6 items*)	activity scale (18 items [†])
Weakness	Grip strength of the dominant hand:	Grip strength of the dominant hand:
	<17 kg for BMI <23	<17kg for BMI <23
	<17.3 kg for 23 < BMI 26	≤17.3 kg for 23 < BMI ≤26
	<18 kg for 26 < BMI 29	<18kg for 26 < BMI <29
	<21 kg for BMI >29	<21 kg for BMI >29

Maximal grip strenght by age in Europe (SHARE Study)





Fried frailty phenotype assessment tool

Fried criteria are the most commonly used frailty instrument in research

However, their use in clinical practice may be limited:
Fried criteria require more time, equipment and expertise
it has been developed in a USA community-dwelling sample
excluding older subjects with cognitive impairment, stroke and
depression.

Fried criteria may be difficult to easily apply to clinical trial populations as well, particularly with regard to the assessment of habitual physical activity and in those having the highest degree of health and functional impairment (e.g. hospitalized subjects, nursing home and assisted living residents).

EMA Reflection paper on frailty: instruments for baseline characterisation of clinical trial older populations EMA/CHMP/778709/2015 2018

Deficit accumulation and Frailty Index (FI)


- Frailty = multidimensional risk state
- Measured by quantity rather than by the nature of health problems.
- Various disorders are accumulated during life.
- The more deficits are accumulated, the more likely that person is to be frail. Deficits can be symptoms, signs, diseases, disabilities, abnormal laboratory measurements
 - Accumulate with age
 - Associated with adverse outcome

Mitnitski et al. 2001; Rockwood and Mitnitski 2007, Searle et al., 2008

Frailty Index based on comprehensive


assessment Canadian Study on Health and Aging, 2004

Appendix 1: List of variables used by the Canadian Study of Health and Aging to construct the 70-item CSHA Frailty Index · Changes in everyday activities · Mood problems · Seizures, partial complex · Head and neck problems · Feeling sad, blue, depressed · Seizures, generalized · Poor muscle tone in neck · History of depressed mood · Syncope or blackouts · Bradykinesia, facial · Tiredness all the time · Headache · Cerebrovascular problems · Problems getting dressed . Depression (clinical impression) · Problems with bothing · Sleep changes · History of stroke · Problems carrying out personal grooming. · Restlessness · History of diabetes mellitus · Urinary incontinence · Memory changes · Arterial hypertension · Yoileting problems · Short-term memory impairment · Peripheral pulses · Bulk difficulties · Cardiac problems · Long-term memory impairment · Rectal problems · Changes in general mental functioning · Myocardial infarction · Gastrointestinal problems . Onset of cognitive symptoms · Anhythmia · Problems cooking · Clouding or delinium · Congestive heart failure · Sucking problems · Paramoid features · Lung problems · Problems going out alone · History relevant to cognitive impairment · Respiratory problems · Impaired mobility · History of thyroid disease · Family history relevant to cognitive · Musculoskoletal problems · Thyroid problems impairment or loss · Bradykinesia of the limbs · Skin problems · Impaired vibration . Power musicle tone in limbs · Malignant disease · Tremor at rest · Poor limb coordination · Breast problems · Postural tremor · Poor coordination, trunk · Abdominal problems · Intention fremor · Foor standing posture · Presence of most reflex · History of Parkinson's disease · Presence of the palmomental reflex · Irregular gait pattern · Family history of degenerative disease · Falk · Other medical history




Prevalence, Attributes, and Outcomes of Fitness and Frailty in Community-Dwelling Older Adults: Report From the Canadian Study of Health and Aging


Journal of Gerontology: MEDICAL SCIENCES 2004, Vol. 59A, No. 12, 1310-1317



Institutionalization



Mortality



Clinical Frailty Scale (CFS)


Based on
Frailty index
or
Comprehensive
clinical assessment

коскwood et al., CMAJ 173(5) 2005

Short instrument for identifying frail patients in clinical practice

Frailty Criteria	porotic Fracture (SOF) Crit Data Collection	Score
Weight loss ≥ 5% over 3 yrs	Weight 3 years ago Weight today Change in weight/ Weight 3 years ago= % loss	Score=1 if weight loss ≥ 5% Otherwise, Score=0
Inability to do 5 chair stands	Sit in chair, do not use arms, rise 5 times	Score=1, if unable Otherwise, Score=0
"Do you feel full of energy?"	Ask the question, must answer yes or no	Score=1, if no Otherwise, Score=0
	227	Sum above scores

Reference: Ensrud KE, Ewing SK, Taylor BC, et al. Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med. 2008 Feb 25;168 (4):382-9



- 1. Weight loss
- 2. Inability to rise from a chair
- 3. Reduced energy level

Ensrud K et al. Arch Intern Med 2008;168:382-

9



9 January 2018 EMA/CHMP/778709/2015 Committee for Medicinal Products for Human Use (CHMP)

Reflection paper on physical frailty: instruments for baseline characterisation of older populations in clinical trials

"...ensuring that population included in the clinical development program is representative of the target patient population' and states that 'vulnerable geriatric patients at high risk of adverse outcomes (so-called "frail" geriatric patients)' are considered 'particularly important to address in the planning of the clinical development program'"

Keywords


Frailty, older people, ICH E7, geriatrics, elderly, baseline characterisation, ageing

Table of contents

Table of contents2
List of Abbreviations
Executive summary
1. Introduction6
2. Scope
3. Legal basis and relevant guidelines7
4. The concept of frailty8
5. Assessment of baseline physical frailty10
5.1. Short Physical Performance Battery (SPPB)11
5.2. Gait speed
6. Conclusion
7. Annex. SPPB and Gait speed 14

This document recommends two measures to describe functional status/ physical performance of vulnerabe elderly patients enrolled into clinical drug trials: SPPB and gait speed

Identifying an at-risk older population



Physical performace tests as markers of frailty


Short Physical Performance Battery (SPPB)

- Walking speed
- Chair stand

27

- Balance test


Guralnik JM, Ferruci L et al, NEJM 1995;332:556-561




SSPPB evaluation

Total score

Appropriate physical performance Pre-frailty Frailty 10-12 points 7-9 points 6 and less







Frailty and polypharmacy: the role of the practice pharmacist



Pharmacist competencies: frailty

- •Understand how to screen for and interpret frailty instruments scores
- Understand the aging physiology and pharmacology in older people and the impact on drug handling
- •Understand how to tackle polypharmacy and co-morbidity safely
- Understand how to deprescribe medications safely and appropriately
- •Understand how to put together/contribute to care plans for older people
- •Understand how to showcase and evaluate your interventions and outcomes.

Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people.

polypharmacy and excessive polypharmacy were associated with frailty with OR 1.77 [1.20-2.61] and 4.47 [2.37-8.42], resp Frailty (hazard ratio [HR] 2.56 [1.63-4.04]) and excessive polypharmacy (HR 1.83 [1.28-2.62]) were independent predictors of mortality.

Frail people with excessive polypharmacy were six times more likely to die during the follow-up period (HR 6.30 [3.09-12.84]).

Herr M et al Pharmacoepidemiol Drug Saf. 2015 (6):637-46.





Seview Article | Open Access | Fublished: 22 May 2022

Scoping Review of Studies Evaluating Frailty and Its Association with Medication Harm

Jonathan Yong Je Lam [5] Michael Barras, Ian A. Scott, Duncan Long, Leila Shafiee Hamani & Nazanin Falconer

Druss & Aging 39, 333-353 (2022) Cite this article

Results:

Overall, frail individuals were at risk of medication harm with rates ranging between 18.7 and 77% across the nine studies. However, whether frailty is an independent predictor of medication harm remains uncertain, as this was only evaluated in one study. The risk of bias assessment identified limitations in methods and reporting with all nine studies.

Multi-morbidity, frailty and self-care: important considerations in treatment with anticoagulation drugs. Outcomes of the AFASTER study.

patients who were assessed as frail or having greater comorbidity were less likely to receive anticoagulant drugs at discharge.

CONCLUSION:

This study highlights multi-morbidity, frailty and self-care to be important considerations in thromboprophylaxis. Shared decision-making with patients and caregivers offers the potential to improve treatment knowledge, adherence and outcomes in this group of patients with complex care needs.

Cardiology and internal medicine

Ferguson C et al Eur J Cardiovasc Nurs. 2016 Apr 1. pii: 1474515116642604

Frailty assessment in the cardiovascular care of older adults.

Epidemiological studies have consistently demonstrated that frailty carries a relative risk of >2 for mortality and morbidity across a spectrum of stable CVD, acute coronary syndromes, heart failure, and surgical and transcatheter interventions.

Frailty contributes valuable prognostic insights incremental to existing risk models and assists clinicians in defining optimal care pathways for their patients.

Interventions designed to improve outcomes in frail elders with CVD such as multidisciplinary cardiac rehabilitation are being actively tested.

Cardiology and internal medicine

Afilalo J et al J Am Coll Cardiol. 2014 Mar 4;63(8):747-62

Prevalence and impact of fall-risk-increasing drugs (FRIDs), polypharmacy, and drug-drug interactions in robust versus frail hospitalised falls patients: a prospective cohort study

Patient hospitalised after fall (N=204)

Frail fallers had significantly higher number of fall-risk-increasing drugs (frail 3.4 \pm 2.2 vs. robust 1.6 \pm 1.5, P < 0.0001), total number of drugs and DDIs.

While on FRIDs recurrent falls were most likely to occur with 1.5 FRIDs in the frail and 2.5 FRIDs in the robust.

Frailty makes a difference in drug-related adverse events

Bennett A et al Drugs Aging. 2014 Mar;31(3):225-32

Sedative load and frailty among communitydwelling population aged ≥65 years

CONCLUSION

Higher sedative load was positively associated with phenotype frailty and the FI. This suggests that careful consideration must be given when prescribing sedatives to frail older adults, who are most vulnerable to adverse drug reactions and adverse health outcomes. The Irish Longitudinal Study on Ageing (TILDA)

Careful drug use in pre-frail/frail seniors

Peklar J et al J Am Med Dir Assoc. 2015 Apr;16(4):282-9

The Importance of Evaluating Frailty and Socialbehavioral Factors for Managing Drugs and Dialysis Prescription in Elderly Patients.

propose that 3 variables:

frailty phenotype,

senile GFR, and

detrimental social-behavioral factors,

should be considered at time of prescribing drugs or medical procedures in the elderly. Additionally, they should also be considered when prescribing therapies in elderly patients suffering from chronic diseases (diabetes mellitus, chronic kidney disease, etc.), or on organ replacement treatments (dialysis and transplantation).

Nephrology

Musso CG et al Drug Res (Stuttg). 2016 Apr;66(4):223-4.

Conclusions I

- Pharmacists more frequently provide consultations to elderly patients
- It is important to distinuish between robust, pre-frail and frail elderly persons to suggest individualized pharmacological treatment
- Frailty is a strong predictor of adverse health outcomes including those related to drug use (polypharmacy, inappropriate drugs, interactions, ADE)
- Pharmacists can use short valid frailty screening tools (e.g. SOF criteria, CFS) and/or know how to interpret frailty scores to identify vulnerable patients

Conclusions II

- Assessing frailty as part of the individualized comprehensive assessment of senior enable to estimate patient's ability to withstand and profit from either standard medical management, modified medical approach or symptomatic (conservative/palliative) treatment.
- Vulnerability should be evaluated also in currently independent patients. Performance tests are recommended (grip strength, gait speed, SPPB)
- In high risk patients (age over 85 yrs, 4+ commorbidities, ADL disability, with geriatric syndromes (dementia, delirium, depression, incontinence, immobility, instability) appropriateness of intervention should be considered.
- For clinical trials EMA recommends proportional participation of older and vulnerable subjects. Baseline status/performance should be assessed using SPPB or gait speed

After this lecture

I hope you all are

